Kornimate/medical-research-clean huggingface dataset:
emotions in the communication and relationship styles of parents with hemophilic children.

Conditions: Hemophilia A

Summary: severe hemophilia is a rare, inherited, x-linked disorder. currently, standard therapy involves ev infusion of drugs from a very young age. the diagnosis of hemophilia is a traumatic event for the parents, even before the unborn child. the management of the hemophilia patient involves the whole family. also in relation to its heredity.focus on the ways in which parents of children with hemophilia manage their emotional experience.

severe hemophilia is a rare, inherited, x-linked disorder. currently, standard therapy involves ev infusion of drugs from a very young age.the diagnosis of hemophilia is a traumatic event for the parents, even before the unborn child. the management of the hemophilia patient involves the whole family. also in relation to its heredity.focus on the ways in which parents of children with hemophilia manage their emotional experience.he diagnosis of hemophilia brings with it, in parents, fears, guilt, overprotective temptations that push us to act rather than to narrate the meaning of that need of ours, caregiving modes that risk engaging our operational side at the expense of recognizing ourselves and our feelings and emotions. we have no reason to think that that traumatic stimulus installs in us an atypical mode of resorting to our emotional intelligence. therefore, it becomes even more significant to study parent-child communication processes on this target, to observe whether and how the adult's emotional area finds its place and expression. on the results of this work, the foundations could be laid for subsequent observational or interventional studies.

Eligibility criteria:
inclusion criteria: * haemophilia a exclusion criteria: * no informed conset
inhaled aerosolized prostacyclin for pulmonary hypertension requiring inhaled nitric oxide

Conditions: Pulmonary Hypertension

Summary: acute secondary pulmonary hypertension (ph) often leads to dysfunction of the right ventricle (rv) and can be a significant cause of patient morbidity and mortality. selective pulmonary vasodilation with inhaled nitric oxide (ino) has become the treatment of choice for this condition. the evidence supporting ino safety and efficacy under these circumstances is sparse, however, and is largely extrapolated from the use of ino in neonatal pulmonary hypertension. moreover, the high cost and potential toxicity of ino makes the therapy far from ideal. emerging evidence suggests that inhaled aerosolized prostacyclins such as iloprost may be a favorable alternative therapy.

phase 1- in the original study, 3 doses of iloprost were given. this was revised after 5 subjects were enrolled in order to study the effects of continuous delivery over a longer period of time. phase 2 - all remaining subjects received iloprost as a continuous treatment. the study was designed for an enrollment of 200 subjects and was ended early.

Eligibility criteria:
inclusion criteria: 1. clinical evidence of pulmonary hypertension (ph) requiring ino therapy as prescribed by the attending physician. 2. indwelling arterial catheter. 3. signed informed consent exclusion criteria: 1. clinically unstable circulatory condition requiring epinephrine \> 0.1 mcg/kg/min or levophed, or already meeting treatment failure criteria (see section 5.3 below) 2. known hypersensitivity to prostacyclin compounds 3. patients receiving sildenafil or bosentan 4. refusal by the attending physician

Keywords: pulmonary hypertension
a long-term study for the treatment of painful diabetic neuropathy

Conditions: Diabetic Neuropathies

Summary: the purpose of the study is to investigate safety and efficacy of duloxetine for patients with painful diabetic neuropathy at long-term use.


Eligibility criteria:
inclusion criteria: * outpatients who have completed the 13-week treatment in the preceding study (protocol no. 0715n0831: nct00552175). * patients who desire to receive continued treatment with ly248686 from the preceding study. * patients with latest glycosylated hemoglobin (hba1c) ≤9.0% before visit 7. * patients who can provide written consent in person. exclusion criteria: * patients who concurrently have serious cardiovascular, hepatic, renal, respiratory, or blood disease, or symptomatic peripheral vascular disease, and thus are considered inappropriate to be included in the study. * pregnant patients or women who desire to become pregnant during the study period, and breast feeding patients. * other patients judged by the investigator/subinvestigator to be inappropriate as a subject in this study.
head-to-head study of 68ga-mgs5 versus 68ga-dotatate pet/ct in patients with medullary thyroid carcinoma

Conditions: Medullary Thyroid Carcinoma

Summary: cholecystokinin-2 (cck2) receptor is overexpressed in more than 90% of mtc cases, and preclinical studies have shown that 68ga-mgs5 (targeting cck2) has good stability in vivo and is promising for diagnosis and staging of mtc. this prospective study will compare the diagnostic effects of 68ga-mgs5 and 68ga-dotatate on mtc primary foci, lymph node metastasis, and distant metastasis, and explore the effect of 68ga-mgs5 pet/ct on the clinical staging (tnm staging) of mtc.

this study was planned to enroll 20 patients with suspected mtc and mtc recurrence who attended the first hospital of fujian medical university from june 2023 onwards. each patient completed pet/ct examination within 1 week, one 68ga-dotatate pet/ct whole-body examination and two 68ga-mgs5 pet/ct whole-body examinations (1 hour and 2 hours after injection, respectively). cck2 immunohistochemical staining and expression scoring of primary foci and lymph node metastases were also performed.

Eligibility criteria:
inclusion criteria: * patients of either gender, aged ≥ 18 years and ≤80 years. * patients with pathologic findings confirming the diagnosis of mtc * patients with mtc recurrence * signed written consent exclusion criteria: * pregnant or breastfeeding female patients * patients with claustrophobic behavior * the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent
personalized management of pancreatic adenocarcinoma using patient-derived tumoroids

Conditions: Pancreas Adenocarcinoma

Summary: this study is designed to prospectively investigate the feasibility of establishing patient-derived tumoroids (pdt) as a platform for a personalized approach for response prediction and guide optimal neoadjuvant and/or adjuvant approach. pdt will be investigated to determine drug sensitivity, predict the response to chemotherapy agents and radiation therapy, and validate this response in treated patients, and to establish the feasibility of pdt as a platform for a personalized approach to guide multimodality treatment.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years of age. * have an ecog performance status of ≤ 2. * no evidence of distant metastasis on imaging. * histologic or cytologic proven adenocarcinoma of the pancreas. * providing informed consent prior to enrollment in the trial. exclusion criteria: * failure to obtain additional core needle biopsies for generating pdts. * females who are pregnant or plan to become pregnant.
managing hypertension among people living with hiv

Conditions: Blood Pressure; Human Immunodeficiency Virus I Infection; Acquired Immunodeficiency Syndrome; Hypertension

Summary: the managing hypertension among people living with hiv: an integrated model (map-it) a stepped wedge, cluster-randomized controlled trial to evaluate the effect of practice facilitation (pf) on the integration of a task-shifting strategy for hypertension (htn) control (tassh) into hiv care for management of htn in people living with hiv (plwh). the study will recruit 960 plwh across 30 primary health centers (phcs) in akwa ibom state (32 patients/phc).

people living with hiv (plwh) are at increased risk for non-communicable diseases (ncds) including cardiovascular diseases (cvd) with hypertension (htn) the most common. integrating ncd management into hiv chronic care services may be a cost-effective strategy to mitigate the rising burden of ncds in plwh. the goal of the study is to evaluate the effectiveness of practice facilitation in the integration of a task-shifting strategy for hypertension control into hiv care service delivered in primary health centers in akwa ibom state, nigeria. this study will occur in two phases: 1) the first phase is a ug3 planning phase during which investigators will use the iparihs implementation science framework to explore factors and support systems required for successful implementation and integration of tassh into existing hiv chronic care platform and development of a context-specific practice facilitation strategy. 2) the second phase, which is the focus of this record, is a uh3 implementation phase during which we will use a stepped-wedge, cluster rct, guided by the re-aim implementation science framework, to evaluate the effect of practice facilitation strategy on the level of adoption of tassh, hypertension control, and level of sustainment of tassh in management of hypertension among 960 patients enrolled in hiv treatment services across 30 phcs.

Eligibility criteria:
inclusion criteria: 1. persons aged 18 years or older 2. be hiv positive and currently enrolled in hiv treatment services at one of the 30 study phcs, be receiving htn treatment services at one of the 30 study phcs, or can be enrolled at one of the 30 study phcs to receive htn services for the entire study duration. 3. have elevated blood pressure between 140-179 mm hg systolic and/or 90-109 mm hg diastolic, as determined by the average of the latter two of three separate bp readings during one clinic visit 4. able to provide consent exclusion criteria: 1. bp ≥180/100 mm hg 2. known history of kidney disease, heart disease, diabetes mellitus, stroke 3. a female who is pregnant or breastfeeding at the time of enrollment 4. inability to provide informed consent 5. refusal to participate in the study

Keywords: noncommunicable diseases cardiovascular diseases health services accessibility hiv nigeria
assessment of usability and satisfaction with a take-home device presenting sound and body stimulation for back pain

Conditions: Chronic Lower Back Pain

Summary: pain symptoms can have a variety of ways to be treated, from medications to physical therapy, with several options being available to patients. however, no one treatment may work for all people who experience pain, especially clbp. the purpose of this study is to measure the compliance, usability, and satisfaction of an at-home, multi-modal stimulation device in a diverse population of people with chronic lower back pain (clbp). the multi-modal device will include a combination of electrical stimulation, auditory stimulation, and integrative-health techniques, including mindfulness breathing, health coaching, and reflective journaling. the multi-modal device creation is based on prior knowledge in lower back pain treatment, which includes electrical stimulation of the back (transcutaneous electrical nerve stimulator or tens) and integrative health modalities. in isolation, these treatments are only somewhat effective in reducing symptoms. this pilot study will involve participants who experience clbp as we investigate a novel at-home, multi-modal device design. the main objective of the pilot usability study is to examine compliance to the intended use of the multi-modal device and approach, as well as protocol feasibility, and satisfaction with the settings and design.


Eligibility criteria:
inclusion criteria: * must be 18 years of age or older * must be within commuting distance to the university of minnesota * able to provide consent and follow study instructions * must be able to understand english * must have chronic lbp, which is defined as lower back pain for more than 3 months * a score of 4 or higher on the peg * must be willing to commit to full duration of the study * not currently taking any benzodiazepines or sedative hypnotics exclusion criteria: * back pain associated with: * spondylolisthesis or spinal stenosis * sciatica or radiculopathy * rhematologic or inflammatory disease * trauma, fracture, dislocation, or previous back surgery * a score of 10 on the peg * pregnant * have an electrically implanted device, such as a pacemaker. * heart disease * epilepsy * cancer * psychiatric conditions including psychosis, suicidal ideation, or substance abuse disorder * a pure tone average of more than 40 db hl at 500 db, 1000 db, or 2000 db hl. * individuals currently using other lower back pain treatments during the study in which they are unable to maintain a steady state while participating in our study for one month before beginning the multi-modal regimen.
virtual reality during the removal of chest drains in critically-ill patients

Conditions: Pain; Anxiety

Summary: appropriate pain and anxiety management of critically-ill patients during bedside procedures remains a big challenge. clinical practice guidelines recommend preemptive analgesia or non-pharmacological interventions, such as relaxation techniques or distraction, to prevent and treat pain during nursing procedures. one of the most painful procedures in the intensive care unit (icu) is the removal of chest drains in post-cardiac surgical patients. virtual reality (vr) is a computer-generated simulation of a 360º immersive world in which the patient can receive visual and auditory stimuli that distract them from the real environment. current research has demonstrated that vr reduced pain and anxiety in intravenous catheter insertions or wound care. the primary objective of the study is to evaluate the effectiveness of vr on pain and anxiety during the removal of chest drains, in post-cardiac surgical patients. the hypothesis is that vr reduces both pain and anxiety, in critically-ill patients, during the removal of chest drains in post-cardiac surgical patients.

this is a prospective, randomized, open-label, prospective study of two parallel groups of patients during the removal of chest drains: group 1: removal of chest drains according to the usual management protocol. group 2: removal of chest drains according to the usual management protocol supplemented by the use of virtual reality glasses (vr glasses)

Eligibility criteria:
inclusion criteria: * patients ≥ 18 years old * patients with richmond agitation-sedation scale (rass) between -1 to rass +1 * patients undergoing cardiac surgery * patients with chest drains * patients who voluntarily agree to participate (informed consent form) exclusion criteria: * patients with a language barrier * patients with cognitive impairments * patients with neuromuscular blockers * patients with a previous history of documented anxiety * patients with epilepsy * hemodynamically unstable patients * face or ocular infections, with could contaminate vr glasses

Keywords: virtual reality glasses
a pilot study of liver protection using prednisone for patients receiving stereotactic body radiation therapy for hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma

Summary: patients on this study will self administer prednisone for three days before starting radiation therapy (rt) and continue to take 60 mg/day during the first three fractions of rt.


Eligibility criteria:
inclusion criteria: * patients with hepatocellular carcinoma are eligible for this trial. hepatocellular carcinoma is defined as having at least one of the following: 1. biopsy proven hepatocellular carcinoma (hcc); or 2. a discrete hepatic tumor(s) as defined by the aasld criteria (80) - for cirrhotic patients, \>1cm with arterial hypervascularity and venous or delayed phase washout on contrast enhanced ct or mri. * patients must have recovered from the acute effects of prior liver-directed therapy (e.g., rt, rfa, or tace), and a minimum of 4 weeks must have passed since the last procedure and protocol therapy. * patients must have a performance status of ≤2. * patients must be 18 years of age or older. * patients with at least one of the following: 1. albi score equal to (-1.81) or higher (worse). this value was calculated as the equivalent albi score for cp score equal 7 in cousins et al study's cohort(59). 2. lesion(s) with a cumulative treatment diameter of ≥ 4cm. 3. cp score equal to 7 or higher (worse). * patients must understand and be willing to sign an informed consent form approved for this purpose by the institutional review board (irb) of the university of michigan medical center indicating that they are aware of the investigational aspects of the treatment and the potential risks. exclusion criteria: * any serious disease, comorbidity or intercurrent illness which precludes delivery of radiation therapy, as determined by the treating investigator. * any contraindication to the administration of steroids, including * documented hypersensitivity to prednisone or any component of the formulation. * systemic fungal infection. * patients with uncontrolled infections or with chronic infections requiring antibiotics. infections are considered controlled if appropriate therapy has been instituted and, at the time of enrollment, no signs of progression are present. progression of infection is defined as hemodynamic instability attributable to sepsis, new symptoms, worsening physical signs or radiographic findings attributable to infection. persisting fever without other signs or symptoms will not be interpreted as progressing infection. * uncontrolled hyperglycemia. * patients with insulin -dependent diabetes. * patients with decompensated liver disease, defined as: clinical ascites requiring paracentesis, hepatic encephalopathy, hepatorenal syndrome or variceal hemorrhage. * active gastrointestinal bleeding within 30 days of enrollment.

Keywords: radiation therapy prednisone
uterus transplantation from deceased donor - gothenburg iii

Conditions: Absolute Uterine Factor Infertility; Transplantation; Mrk Anomaly

Summary: deceased donor uterus transplantation will be offered to patients that have either been excluded from gothenburg ii because of donor criteria or because of early graft failure in gothenburg i and ii


Eligibility criteria:
inclusion criteria recipient * initially included with ivf and excluded by donor issues of gothenburg i or ii * initially included and excluded by early graft failure of gothenburg i or ii * age \< 40 years * no systemic disease * no standing medication * satisfactory ovarian reserve * bmi \<35 and at bmi 30-35 waist circumference of \< 82 cm * absolute uterine factor infertility * psychological stable inclusion criteria donor * brain death and suitable as multiorgan donor * acceptance for donation of uterus from family or previously by patient * age \<55 years * at least one normal pregnancy and childbirth * no previos malignancy * no systemic disease * no previous major surgery inn abdomen or on uterus

Keywords: infertility, uterus, transplantation, mrkh
development of a virtual stress inoculation training (sit) platform and mobile health app

Conditions: PTSD; Trauma and Stressor Related Disorders; Traumatic Brain Injury

Summary: the purpose of this study is to demonstrate the feasibility and utility of sit delivered asynchronously (self-paced) via fully virtual platform with and without the aid of a mobile health application and to determine initial change over baseline in terms of reduction in ptsd symptoms and improvement in resiliency in participants receiving the virtual sit prototype, using linear mixed models (lmms),


Eligibility criteria:
inclusion criteria: * us military veterans / service members * diagnosis of ptsd as measured by a posttraumatic symptom checklist for dsm-5 (pcl-5) score of \>33 * history of combat trauma and/or military service in an imminent danger pay area * be fluent in english. * be capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form and in this protocol. * have access to a smartphone or tablet to utilize the mobile health app and/or access the virtual classroom. * agree to undergo psychometric testing and participate in ongoing assessments throughout the study duration. * be willing to comply with all study procedures, able to complete all assessments independently, and available for the duration of the study. exclusion criteria: * active suicidal ideation as assessed by the investigator at screening or as identified during the study. * clinically significant history of psychotic disorder, bipolar spectrum disorder, or neurodegenerative disease/dementia as assessed by the investigator. * active severe substance abuse as assessed by the investigator in accordance with dsm-5 substance abuse disorder criteria, an audit score \> 15, or partial brief addiction monitor (bam) indicating the presence of illicit substance use other than cannabis (\< 3 times weekly). * they are currently undergoing another form of treatment other than supportive therapy (\> 2 times per month). * engaged in active trauma-focused therapy including cognitive processing therapy (cpt)prolonged exposure (pe), or eye movement desensitization and reprocessing (emdr). * any other condition/situation that the investigator believes may interfere with participant safety, study conduct, or interpretation of study data.

Keywords: veteran post traumatic stress disorder (ptsd) traumatic brain injury military
optimization of asthma treatment through exhaled no for increased asthma-related quality of life (noak)

Conditions: Allergic Asthma

Summary: the purpose of this study is to determine whether use of exhaled no (nitric oxide) to regulate the anti-inflammatory treatment leads to increased asthma-related quality of life in patients with allergic asthma


Eligibility criteria:
inclusion criteria: * age 18-64 * clinical diagnosis of asthma * glucocorticoid treatment \> 6 months. * verified allergy * read and speak swedish exclusion criteria: * smoking * current regular treatment with long-acting beta2-agonist * treatment with singulair only or in combination with glucocorticoids * taking part in other research study * pregnancy or breast-feeding * unstable asthma

Keywords: asthma allergy cytokines glucocorticoids inflammation nitric oxide (no) quality of life self-rated health stress